A Phase 3 interventional study of Semaglutide and Placebo (Semaglutide) in Heart Failure With Preserved Ejection Fraction (HFpEF) and Diabetes Mellitus, Type 2, sponsored by Novo Nordisk A/S. Completed at 180 sites in 16 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Novo Nordisk A/S · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 82 studies testing semaglutide in Diabetes Mellitus — 12 open to participants now, 14 under way, 2 of them phase 3. Semaglutide · Diabetes Mellitus.
Among the 82 studies testing semaglutide in Diabetes Mellitus, this one is the 16th largest by enrollment, is one of 2 that started in 2021, is one of 26 in phase 3, and was the 63rd registered.
8,293 studies on the registry are indexed under Diabetes Mellitus; 1,072 are open to participants now.
Browse Diabetes Mellitus studies →12 of the 82 studies testing semaglutide in Diabetes Mellitus are open now, in 8 countries. Recruiting first, the newest first:
Mapi Pharma Ltd. · Sites in Israel
Ages 18–64
Hospital Universitario Dr. Jose E. Gonzalez · Sites in Mexico
Ages 18+
Unity Health Toronto · Sites in Canada
Ages 18+
Second Affiliated Hospital of Guangzhou Medical University · Sites in China
Ages 18–65
McGill University Health Centre/Research Institute of the McGill University Health Centre · Sites in Canada
By country, each count listing its studies:
Semaglutide: first FDA approval 2017 (OZEMPIC), first EMA approval 2018. What it is approved for, and how studies give it, is on its page →
Of the 648 Diabetes Mellitus studies recruiting now, 357 (55%) set no upper age limit and 195 (30%) stop at 75 or younger; 88 take children under 18; 182 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
On this site’s reading of the record, semaglutide is the treatment under test here. Read study by study →
82 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 38 · Phase 2 7 · Phase 3 27 · Phase 4 10
First in 2007; this study’s year is marked. 2 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 617 is above the median of 80 across 6,025 interventional studies indexed under Diabetes Mellitus.
Median enrollment 100 across the 82 interventional studies. Of the 66 that completed or were terminated, 28 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
64 of 82 have an industry lead sponsor. The 10 most frequent:
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
642 studies in Diabetes Mellitus by Novo Nordisk A/S: 2 open now, 3 under way, 1 of them phase 3. Of 636 finished, 163 (26%) have results posted.
Among the 642 studies in Diabetes Mellitus by Novo Nordisk A/S, this one is the 53rd largest by enrollment of the 494 interventional ones that give a count, is the only one that started in 2021, is one of 182 in phase 3, and was the 638th registered.
Novo Nordisk A/S’s Diabetes Mellitus studies by the year they started, since 1989.
6 of the studies testing semaglutide in Diabetes Mellitus that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06387199Phase 3McGill University Health Centre/Research Institute of the McGill University Health CentreAlleviating Carbohydrate Counting for Patients with Type-1 Diabetes Using a Closed Loop System with Weekly Subcutaneous Semaglutide | 2027-01 |
| NCT05195944University Health Network, TorontoSemaglutide vs Sitagliptin | 2026-12 |
| NCT06715514Lia BallyMenopausal Hormone Therapy, GLP-1 Agonists, and Glucose and Energy Homeostasis in Postmenopausal Women With Overweight/Obesity and Impaired Glucose Homeostasis | 2026-12-17 |
| NCT06959784China-Japan Friendship HospitalAssessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study) | 2026-12-31 |
| NCT07401992Hospital Universitario Dr. Jose E. GonzalezEffects of Semaglutide on Clinical Outcomes and Metabolic Inflammation in Psoriasis | 2027-02-28 |
Add all 6 to your calendar (.ics) → With an account.
Among the 82 studies testing semaglutide in Diabetes Mellitus, from their registry updates:
Among Novo Nordisk A/S’s 642 in Diabetes Mellitus:
This tab as a report to print or save as PDF → With an account.
This study will look at how participants' daily life is affected by their heart failure. The study will also look at the change in participants' body weight.
This study will compare the effect of semaglutide (a new medicine) compared to "dummy" medicine on body weight and heart failure symptoms.
Participants will either get semaglutide or "dummy" medicine, which treatment participants get is decided by chance.
Participants will need to take 1 injection once a week. The study medicine is injected with a thin needle in a skin fold in the stomach area, thigh or upper arm.
During the study participants will have talks with the study staff about healthy lifestyle and physical activity.
The study will last for about 59 weeks, that is a little more than 1 year. Participants will have 12 clinic visits with the study doctor.
Women cannot take part if pregnant, breast-feeding or plan to become pregnant during the study period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive semaglutide injections for 52 weeks.
Drug: Semaglutide
Participants will receive semaglutide placebo injections for 52 weeks.
Drug: Placebo (Semaglutide)
Participants will receive semaglutide subcutaneous (s.c.; under the skin) injection(s) once-weekly for 52 weeks. Dose will be gradually increased to 2.4 mg: 0.25 mg from week 1 to 4, 0.5 mg from week 5 to 8, 1.0 mg from week 9 to 12, 1.7 mg from week 13 to 16 and 2.4 mg from week 17 to week 52.
Participants will receive semaglutide matching placebo s.c. injection(s) once-weekly for 52 weeks.
Change in KCCQ (Kansas City Cardiomyopathy Questionnaire) Clinical Summary Score
Change in KCCQ-Clinical Summary Score (CSS) from baseline (week 0) to end of treatment (week 52) is presented. The KCCQ is a standardised 23-item, self-administered instrument that quantifies heart failure symptoms (frequency, severity, and recent change), physical limitation, quality of life (QOL), and social limitation. Scores were transformed to a range of 0 to 100 in which higher scores reflected better health status. KCCQ-Clinical Summary Score (CSS) included the symptom and physical limitation domains of the KCCQ. The outcome data was evaluated based on the in-trial observation period. The in-trial period was defined as the time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death).
Time frame: Baseline (week 0), end of treatment (week 52)
Percentage Change in Body Weight
Percentage change in body weight from baseline (week 0) to end of treatment (week 52) is presented. The outcome data was evaluated based on the in-trial observation period. The in-trial period was defined as the time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death).
Time frame: Baseline (week 0), end of treatment (week 52)
Change in Six-minute Walking Distance
Change in six-minute walking distance from baseline (week 0) to end of treatment (week 52) is presented. The 6 Minute Walk Test is a direct and timed measure of walk distance. The goal is for the subject to walk as far as possible in six minutes without running. The outcome data was evaluated based on the in-trial observation period. The in-trial period was defined as the time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death).
Time frame: Baseline (week 0), end of treatment (week 52)
Hierarchical Composite Endpoint: Total Number of Wins for Each Treatment Group
Hierarchical composite outcome measure from baseline (week 0) to end of trial (week 57) is presented. Analysis of the hierarchical composite endpoint was based on direct comparisons of each participant randomised to semaglutide 2.4 mg and placebo within each stratum. A 'treatment winner' (1000 imputations) based on similar observation time was declared based on endpoint hierarchy. Outcome data was evaluated based on in-trial observation period which was defined as time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death). Missing observations at week 52 for KCCQ-CSS and body weight were multiple (x1000) imputed (by MAR assumption) using available measurements at week 52 from participants of same randomized treatment arm. Missing observations due to CV death or previous HF event were single imputed using change from baseline to overall lowest KCCQ-CSS value across treatment arms and time points.
Time frame: Baseline (week 0), end of trial (week 57)
Change in C-Reactive Protein
Change in C-Reactive Protein from baseline (week -2) to end of treatment (week 52) is presented. The outcome data was evaluated based on the in-trial observation period. The in-trial period was defined as the time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death).
Time frame: From baseline (week -2) to end of treatment (week 52)
Participants Achieving 10% Weight Loss or More (Yes/No)
Participants achieving 10% weight loss or more (Yes/No) at week 52 is presented. In the reported data, 'Yes' infers number of participants who have achieved 10% weight loss or more whereas 'No' infers number of participants who have not achieved 10% weight loss or more. The outcome data was evaluated based on the in-trial observation period. The in-trial period was defined as the time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death).
Time frame: At Week 52
Participants Achieving 15% Weight Loss or More (Yes/No)
Participants achieving 15% weight loss or more (Yes/No) at week 52 is presented. In the reported data, 'Yes' infers number of participants who have achieved 15% weight loss or more whereas 'No' infers number of participants who have not achieved 15% weight loss or more. The outcome data was evaluated based on the in-trial observation period. The in-trial period was defined as the time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death).
Time frame: At Week 52
Participants Achieving 20% Weight Loss or More (Yes/No)
Participants achieving 20% weight loss or more (Yes/No) at week 52 is presented. In the reported data, 'Yes' infers number of participants who have achieved 20% weight loss or more whereas 'No' infers number of participants who have not achieved 20% weight loss or more. The outcome data was evaluated based on the in-trial observation period. The in-trial period was defined as the time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death).
Time frame: At Week 52
Participants Improving 5 Points or More in KCCQ Clinical Summary Score (Yes/No)
Participants improving 5 points or more in KCCQ clinical summary score (Yes/No) at week 52 is presented. The KCCQ is a standardised 23-item, self-administered instrument that quantifies heart failure symptoms (frequency, severity, and recent change), physical limitation, quality of life (QOL), and social limitation. Scores were transformed to a range of 0 to 100 in which higher scores reflected better health status. KCCQ-CSS included the symptom and physical limitation domains of the KCCQ. In the reported data, 'Yes' infers number of participants who have improved 5 points or more in score whereas 'No' infers number of participants who have not improved 5 points or more in score. The outcome data was evaluated based on the in-trial observation period. The in-trial period was defined as the time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death).
Time frame: At Week 52
Participants Improving 10 Points or More in KCCQ Clinical Summary Score (Yes/No)
Participants improving 10 points or more in KCCQ clinical summary score (Yes/No) at week 52 is presented. The KCCQ is a standardised 23-item, self-administered instrument that quantifies heart failure symptoms (frequency, severity, and recent change), physical limitation, quality of life (QOL), and social limitation. Scores were transformed to a range of 0 to 100 in which higher scores reflected better health status. KCCQ-CSS included the symptom and physical limitation domains of the KCCQ. In reported data, 'Yes' infers number of participants who have improved 10 points or more in score whereas 'No' infers number of participants who have not improved 10 points or more in score. The outcome data was evaluated based on the in-trial observation period. The in-trial period was defined as the time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death).
Time frame: At Week 52
Change in KCCQ Overall Summary Score
Change in KCCQ overall summary score from baseline (week 0) to end of treatment (week 52) is presented. The KCCQ is a standardised 23-item, self-administered instrument that quantifies heart failure symptoms (frequency, severity, and recent change), physical limitation, QOL, and social limitation. Scores are transformed to a range of 0 to 100 in which higher scores reflect better health status. KCCQ- overall summary score (OSS) included the symptom, physical limitation, quality of life, and social limitation domains. The outcome data was evaluated based on the in-trial observation period. The in-trial period was defined as the time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death).
Time frame: Baseline (week 0), end of treatment (week 52)
Participants Achieving Threshold for Clinically Meaningful Within-participant Change in KCCQ-CSS (PGI-S)
Participants achieving threshold for clinically meaningful within-participant change (based on participant perspective) in KCCQ-CSS (Patient Global Impression of Status \[PGI-S\]) at week 52 is presented. KCCQ is a standardised 23-item instrument that quantifies heart failure symptoms (frequency, severity, and recent change), physical limitation, QOL, and social limitation. Scores are transformed to a range of 0 to 100 where higher scores reflect better health status. KCCQ-CSS includes the symptom and physical limitation domains of KCCQ. PGI-S for KCCQ was used to rate participants' symptoms of heart failure in last two weeks using a 4-category ordinal scale (no symptoms, mild, moderate, severe). The threshold of 16.3 points is based on PGI-S for KCCQ-CSS. Outcome data was evaluated based on in-trial period. In-trial period was defined as time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death).
Time frame: At Week 52
Participants Achieving Threshold for Clinically Meaningful Within-participant Change in Six Minute Walking Distance (6MWD) (PGI-S)
Participants achieving threshold for clinically meaningful within-participant change in 6MWD (PGI-S) at week 52 is presented. The six minute walk test (6MWT) is a direct and timed measure of walk distance. The goal is for the subject to walk as far as possible in six minutes without running. The PGI-S for 6MWT was used to rate any difficulty that participants were experiencing in walking quickly using a 5-category ordinal scale (not at all difficult, a little difficult, moderately difficult, very difficult, or unable to walk quickly). The threshold of 16.2 meters is based on PGI-S for 6MWT. The outcome data was evaluated based on the in-trial observation period. The in-trial period was defined as the time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death).
Time frame: At Week 52
Change in Waist Circumference
Change in waist circumference from baseline (week 0) to end of treatment (week 52) is presented. The outcome data was evaluated based on the in-trial observation period. The in-trial period was defined as the time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death).
Time frame: From baseline (week 0) to end of treatment (week 52)
Change in Systolic Blood Pressure
Change in systolic blood pressure from baseline (week -2) to end of treatment (week 52) is presented. The outcome data was evaluated based on the in-trial observation period. The in-trial period was defined as the time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death).
Time frame: Bseline (week -2), end of treatment (week 52)
Change in Glycated Haemoglobin (HbA1c)
Change in HbA1c from baseline (week 0) to end of treatment (week 52) is presented. The outcome data was evaluated based on the in-trial observation period. The in-trial period was defined as the time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death).
Time frame: Baseline (week 0), end of treatment (week 52)
Number of Treatment Emergent Severe or Clinically Significant Hypoglycaemia Episodes
Number of treatment emergent severe or clinically significant hypoglycaemia episodes from baseline (week 0) to end of trial (week 57) is presented. Clinically significant hypoglycemic episode is defined as blood glucose concentration of less than 54 milligrams per deciliter (mg/dL) which is sufficiently low to indicate serious, clinically important hypoglycaemia. Severe hypoglycemic episode is defined as hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery. The outcome data was evaluated based on on-treatment period. A time-point was considered as 'on-treatment' if any dose of trial product had been administered within the prior 5 weeks (35 days).
Time frame: From baseline (week 0) to end of trial (week 57)
The trial was conducted at 108 sites in 16 countries as follows (number of sites that screened participants/number of sites that randomised participants): Argentina (6/6), Austria (4/4), Canada (7/6), Czech Republic (4/4) Germany (7/7), Hungary (10/10), India (9/9), Israel (5/5), Italy (6/6), Japan (7/6), Netherlands (5/5), Poland (6/6), Spain (3/3), Sweden (2/2), United Kingdom (7/7) and United States (26/22).
| Milestone | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Started | 310 | 307 |
| Full analysis set | 310 | 306 |
| Safety analysis set | 310 | 306 |
| Completed | 292 | 291 |
| Not completed | 18 | 16 |
| Withdrew: Withdrawal by subject | 5 | 4 |
| Withdrew: Lost to follow-up | 7 | 2 |
| Withdrew: Death | 6 | 10 |
Change in KCCQ-Clinical Summary Score (CSS) from baseline (week 0) to end of treatment (week 52) is presented. The KCCQ is a standardised 23-item, self-administered instrument that quantifies heart failure symptoms (frequency, severity, and recent change), physical limitation, quality of life (QOL), and social limitation. Scores were transformed to a range of 0 to 100 in which higher scores reflected better health status. KCCQ-Clinical Summary Score (CSS) included the symptom and physical limitation domains of the KCCQ. The outcome data was evaluated based on the in-trial observation period. The in-trial period was defined as the time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death).
| Score on a scale | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Change in KCCQ (Kansas City Cardiomyopathy Questionnaire) Clinical Summary Score | 14.4 ± 18.3 | 7.6 ± 18.8 |
Percentage change in body weight from baseline (week 0) to end of treatment (week 52) is presented. The outcome data was evaluated based on the in-trial observation period. The in-trial period was defined as the time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death).
| Percentage change in body weight | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Percentage Change in Body Weight | -10.2 ± 6.8 | -3.2 ± 5.9 |
Change in six-minute walking distance from baseline (week 0) to end of treatment (week 52) is presented. The 6 Minute Walk Test is a direct and timed measure of walk distance. The goal is for the subject to walk as far as possible in six minutes without running. The outcome data was evaluated based on the in-trial observation period. The in-trial period was defined as the time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death).
| Meters | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Change in Six-minute Walking Distance | 16.9 ± 54.3 | 3.8 ± 49.8 |
Hierarchical composite outcome measure from baseline (week 0) to end of trial (week 57) is presented. Analysis of the hierarchical composite endpoint was based on direct comparisons of each participant randomised to semaglutide 2.4 mg and placebo within each stratum. A 'treatment winner' (1000 imputations) based on similar observation time was declared based on endpoint hierarchy. Outcome data was evaluated based on in-trial observation period which was defined as time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death). Missing observations at week 52 for KCCQ-CSS and body weight were multiple (x1000) imputed (by MAR assumption) using available measurements at week 52 from participants of same randomized treatment arm. Missing observations due to CV death or previous HF event were single imputed using change from baseline to overall lowest KCCQ-CSS value across treatment arms and time points.
| Number of wins | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Time to all-cause death | 2796 | 1814 |
| Number of heart failure events | 4434 | 1171 |
| Time to first heart failure event | 34 | 26 |
| Change in KCCQ-CSS greater than or equal to (>=)15 point difference | 30618 | 17303 |
| Change in KCCQ-CSS >=10 point difference | 6250 | 4763 |
| Change in KCCQ-CSS >=5 point difference | 6925 | 5912 |
| Change in six minute walking distance (6MWD) >=30 metre difference | 4607 | 3920 |
Change in C-Reactive Protein from baseline (week -2) to end of treatment (week 52) is presented. The outcome data was evaluated based on the in-trial observation period. The in-trial period was defined as the time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death).
| Ratio to baseline of C-Reactive Protein | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Change in C-Reactive Protein | 0.58 ± 146.6 | 0.91 ± 128.4 |
Participants achieving 10% weight loss or more (Yes/No) at week 52 is presented. In the reported data, 'Yes' infers number of participants who have achieved 10% weight loss or more whereas 'No' infers number of participants who have not achieved 10% weight loss or more. The outcome data was evaluated based on the in-trial observation period. The in-trial period was defined as the time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death).
| Participants | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Yes | 147 | 29 |
| No | 139 | 249 |
Participants achieving 15% weight loss or more (Yes/No) at week 52 is presented. In the reported data, 'Yes' infers number of participants who have achieved 15% weight loss or more whereas 'No' infers number of participants who have not achieved 15% weight loss or more. The outcome data was evaluated based on the in-trial observation period. The in-trial period was defined as the time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death).
| Participants | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Yes | 64 | 11 |
| No | 222 | 267 |
Participants achieving 20% weight loss or more (Yes/No) at week 52 is presented. In the reported data, 'Yes' infers number of participants who have achieved 20% weight loss or more whereas 'No' infers number of participants who have not achieved 20% weight loss or more. The outcome data was evaluated based on the in-trial observation period. The in-trial period was defined as the time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death).
| Participants | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Yes | 21 | 5 |
| No | 265 | 273 |
Participants improving 5 points or more in KCCQ clinical summary score (Yes/No) at week 52 is presented. The KCCQ is a standardised 23-item, self-administered instrument that quantifies heart failure symptoms (frequency, severity, and recent change), physical limitation, quality of life (QOL), and social limitation. Scores were transformed to a range of 0 to 100 in which higher scores reflected better health status. KCCQ-CSS included the symptom and physical limitation domains of the KCCQ. In the reported data, 'Yes' infers number of participants who have improved 5 points or more in score whereas 'No' infers number of participants who have not improved 5 points or more in score. The outcome data was evaluated based on the in-trial observation period. The in-trial period was defined as the time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death).
| Participants | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Yes | 205 | 149 |
| No | 76 | 123 |
Participants improving 10 points or more in KCCQ clinical summary score (Yes/No) at week 52 is presented. The KCCQ is a standardised 23-item, self-administered instrument that quantifies heart failure symptoms (frequency, severity, and recent change), physical limitation, quality of life (QOL), and social limitation. Scores were transformed to a range of 0 to 100 in which higher scores reflected better health status. KCCQ-CSS included the symptom and physical limitation domains of the KCCQ. In reported data, 'Yes' infers number of participants who have improved 10 points or more in score whereas 'No' infers number of participants who have not improved 10 points or more in score. The outcome data was evaluated based on the in-trial observation period. The in-trial period was defined as the time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death).
| Participants | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Yes | 163 | 116 |
| No | 118 | 156 |
Change in KCCQ overall summary score from baseline (week 0) to end of treatment (week 52) is presented. The KCCQ is a standardised 23-item, self-administered instrument that quantifies heart failure symptoms (frequency, severity, and recent change), physical limitation, QOL, and social limitation. Scores are transformed to a range of 0 to 100 in which higher scores reflect better health status. KCCQ- overall summary score (OSS) included the symptom, physical limitation, quality of life, and social limitation domains. The outcome data was evaluated based on the in-trial observation period. The in-trial period was defined as the time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death).
| Score on a scale | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Change in KCCQ Overall Summary Score | 14.4 ± 18.1 | 7.6 ± 18.6 |
Participants achieving threshold for clinically meaningful within-participant change (based on participant perspective) in KCCQ-CSS (Patient Global Impression of Status \[PGI-S\]) at week 52 is presented. KCCQ is a standardised 23-item instrument that quantifies heart failure symptoms (frequency, severity, and recent change), physical limitation, QOL, and social limitation. Scores are transformed to a range of 0 to 100 where higher scores reflect better health status. KCCQ-CSS includes the symptom and physical limitation domains of KCCQ. PGI-S for KCCQ was used to rate participants' symptoms of heart failure in last two weeks using a 4-category ordinal scale (no symptoms, mild, moderate, severe). The threshold of 16.3 points is based on PGI-S for KCCQ-CSS. Outcome data was evaluated based on in-trial period. In-trial period was defined as time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death).
| Participants | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Participants Achieving Threshold for Clinically Meaningful Within-participant Change in KCCQ-CSS (PGI-S) | 120 | 83 |
Participants achieving threshold for clinically meaningful within-participant change in 6MWD (PGI-S) at week 52 is presented. The six minute walk test (6MWT) is a direct and timed measure of walk distance. The goal is for the subject to walk as far as possible in six minutes without running. The PGI-S for 6MWT was used to rate any difficulty that participants were experiencing in walking quickly using a 5-category ordinal scale (not at all difficult, a little difficult, moderately difficult, very difficult, or unable to walk quickly). The threshold of 16.2 meters is based on PGI-S for 6MWT. The outcome data was evaluated based on the in-trial observation period. The in-trial period was defined as the time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death).
| Participants | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Participants Achieving Threshold for Clinically Meaningful Within-participant Change in Six Minute Walking Distance (6MWD) (PGI-S) | 148 | 104 |
Change in waist circumference from baseline (week 0) to end of treatment (week 52) is presented. The outcome data was evaluated based on the in-trial observation period. The in-trial period was defined as the time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death).
| Centimetre (cm) | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Change in Waist Circumference | -8.9 ± 7.9 | -2.4 ± 7.2 |
Change in systolic blood pressure from baseline (week -2) to end of treatment (week 52) is presented. The outcome data was evaluated based on the in-trial observation period. The in-trial period was defined as the time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death).
| Millimetre of mercury (mmHg) | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Change in Systolic Blood Pressure | -4.0 ± 16.9 | -2.9 ± 16.8 |
Change in HbA1c from baseline (week 0) to end of treatment (week 52) is presented. The outcome data was evaluated based on the in-trial observation period. The in-trial period was defined as the time interval from date of randomisation to date of last contact with trial site (or date of withdrawal of informed consent or death).
| Percentage of HbA1c | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Change in Glycated Haemoglobin (HbA1c) | -0.8 ± 1.1 | 0.1 ± 0.9 |
Number of treatment emergent severe or clinically significant hypoglycaemia episodes from baseline (week 0) to end of trial (week 57) is presented. Clinically significant hypoglycemic episode is defined as blood glucose concentration of less than 54 milligrams per deciliter (mg/dL) which is sufficiently low to indicate serious, clinically important hypoglycaemia. Severe hypoglycemic episode is defined as hypoglycaemia associated with severe cognitive impairment requiring external assistance for recovery. The outcome data was evaluated based on on-treatment period. A time-point was considered as 'on-treatment' if any dose of trial product had been administered within the prior 5 weeks (35 days).
| Episodes | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Number of Treatment Emergent Severe or Clinically Significant Hypoglycaemia Episodes | 20 | 30 |
Collected over From baseline (week 0) to end of trial (week 57). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Semaglutide 2.4 mg | 6/310 (1.9%) | 55/310 (17.7%) | 104/310 (33.5%) |
| Placebo | 10/306 (3.3%) | 88/306 (28.8%) | 60/306 (19.6%) |
| Event | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Cardiac failureCardiac disorders | 4/310 | 22/306 |
| PneumoniaInfections and infestations | 3/310 | 9/306 |
| Atrial fibrillationCardiac disorders | 5/310 | 6/306 |
| Acute myocardial infarctionCardiac disorders | 1/310 | 5/306 |
| Acute kidney injuryRenal and urinary disorders | 2/310 | 4/306 |
| COVID-19Infections and infestations | 3/310 | 3/306 |
| Cardiac failure acuteCardiac disorders | 2/310 | 3/306 |
| Cardiac failure congestiveCardiac disorders | 2/310 | 3/306 |
| OsteoarthritisMusculoskeletal and connective tissue disorders | 2/310 | 3/306 |
| Renal failureRenal and urinary disorders | 0/310 | 3/306 |
| Event | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| NauseaGastrointestinal disorders | 55/310 | 18/306 |
| DiarrhoeaGastrointestinal disorders | 42/310 | 20/306 |
| COVID-19Infections and infestations | 26/310 | 31/306 |
| Cardiac failureCardiac disorders | 13/310 | 30/306 |
| VomitingGastrointestinal disorders | 26/310 | 7/306 |
| Decreased appetiteMetabolism and nutrition disorders | 16/310 | 10/306 |
Full analysis set (FAS) included all randomised participants. 1 eligible participant did not attend the randomisation visit (visit 2) and was randomised in absence by administrative error to placebo; thus, it was decided to exclude the participant from the FAS.
| Age, Continuous(Years) | Semaglutide 2.4 mg | Placebo | Total |
|---|---|---|---|
| Mean | 68 ± 9 | 69 ± 9 | 68 ± 9 |
| Sex: Female, Male(Participants) | Semaglutide 2.4 mg | Placebo | Total |
|---|---|---|---|
| Female | 128 | 145 | 273 |
| Male | 182 | 161 | 343 |
| Ethnicity (NIH/OMB)(Participants) | Semaglutide 2.4 mg | Placebo | Total |
|---|---|---|---|
| Hispanic or Latino | 38 | 38 | 76 |
| Not Hispanic or Latino | 272 | 268 | 540 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race/Ethnicity, Customized(Participants) | Semaglutide 2.4 mg | Placebo | Total |
|---|---|---|---|
| Asian | 45 | 31 | 76 |
| Black or African American | 13 | 5 | 18 |
| White | 251 | 268 | 519 |
| Other | 1 | 2 | 3 |
| Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS)(Score on a scale) | Semaglutide 2.4 mg | Placebo | Total |
|---|---|---|---|
| Mean | 58.8 ± 20.3 | 56.4 ± 19.7 | 57.6 ± 20.0 |
| Body weight(Kilograms (kg)) | Semaglutide 2.4 mg | Placebo | Total |
|---|---|---|---|
| Mean | 106.4 ± 20.9 | 105.2 ± 21.4 | 105.8 ± 21.1 |
| Six minute walking test(Meters (m)) | Semaglutide 2.4 mg | Placebo | Total |
|---|---|---|---|
| Mean | 279.7 ± 96.6 | 276.7 ± 93.5 | 278.2 ± 95.0 |
| High Sensitive C-Reactive Protein(Milligrams per liter (mg/L)) | Semaglutide 2.4 mg | Placebo | Total |
|---|---|---|---|
| Mean | 6.7 ± 9.0 | 7.2 ± 14.1 | 6.9 ± 11.8 |
Showing the first 100 of 180 sites across 16 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · novonordisk-trials.com
Ran from Jun 2021 to primary completion in Oct 2023, 27 months.
Results were first posted in Nov 2026, 3 years after primary completion. A results delay was requested in Oct 2024.
Of 167 industry-sponsored phase 3 interventional studies under Diabetes Mellitus, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 23. This study's 27 months is above that.
Counting every sponsor, half of 230 studies reached it within 19 months; a quarter within 13 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Semaglutide